Joseph K Belanoff Sells $3.4M of Corcept Therapeutics Inc (CORT) — SEC Form 4, Oct 03, 2025
Open-Market Net Sale · SEC Form 4
−$3,403,252
10b5-1 Plan
Equity position changed by -1.4%
Equity Position
2.78M sh
2,821,370 → 2,781,370
Equity Change
-1.4%
shares held after vs before
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Joseph K Belanoff CIK 0001286199 |
Director
CEO
|
Joseph K Belanoff at Corcept Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$10,384,853
More from this insider at Corcept Therapeutics Inc
| 2026-06-02 | Sell | -$895,252 | View |
| 2026-05-05 | Sell | -$2,003,860 | View |
| 2026-03-27 | Sell | -$1,311,826 | View |
| 2026-03-03 | Award | — | View |
| 2025-12-29 | Exercise | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1F2F3 | 2025-10-01 | S - Sale 10b5-1 | 5,616 D | $84.29 | -$473,370 | 2,815,754 | Indirect Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 |
| Common StockF1F4F3 | 2025-10-01 | S - Sale 10b5-1 | 31,190 D | $85.16 | -$2,656,265 | 2,784,564 | Indirect Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 |
| Common StockF1F5F3 | 2025-10-01 | S - Sale 10b5-1 | 3,194 D | $85.67 | -$273,618 | 2,781,370 | Indirect Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 |
Footnotes (5)
- F1
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. Show more
- F2
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.58 to $84.53 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Show more
- F3
- Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Show more
- F4
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.5875 to $85.575 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Show more
- F5
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.63 to $85.785 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Show more
Remarks
The power of attorney under which this form was signed is on file with the Commission.
Show moreRelated filings at Corcept Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
425
institutional managers reporting a position
Largest by reported value
- Black Rock, Inc. $1.08B
- Ingalls & Snyder Llc $690M
- Renaissance Technologies Llc $457M
5%+ Holders · 13D/G
3 filers
-
Black Rock, Inc. 8.9%
-
Ingalls & Snyder Llc 6.8%
-
Joseph K. Belanoff 6.3%
Other insiders at Corcept Therapeutics Inc
-
James N Wilson -$1.15M
-
Roberto Wandenkolk Vieira -$967K
-
Joseph Douglas Lyon -$1.16M
-
Sean Maduck -$2.91M
GET /v1/forms/4/0001193125-25-230467
API docs
View Original SEC Filing